| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Flow Cytometry | 38 | 2024 | 5870 | 4.670 |
Why?
|
| Lymphoma, T-Cell | 16 | 2018 | 305 | 3.120 |
Why?
|
| Immunophenotyping | 39 | 2024 | 1871 | 2.770 |
Why?
|
| Lymphoma, B-Cell | 20 | 2022 | 935 | 2.340 |
Why?
|
| Antigens, CD | 23 | 2017 | 4000 | 2.210 |
Why?
|
| Lymphoma, T-Cell, Peripheral | 7 | 2022 | 124 | 2.020 |
Why?
|
| Mastocytosis, Systemic | 4 | 2015 | 102 | 1.640 |
Why?
|
| Lymphoproliferative Disorders | 9 | 2020 | 533 | 1.390 |
Why?
|
| Leukemia, T-Cell | 3 | 2017 | 101 | 1.170 |
Why?
|
| Laboratory Proficiency Testing | 3 | 2024 | 20 | 1.170 |
Why?
|
| Neoplasms, Plasma Cell | 2 | 2024 | 39 | 1.110 |
Why?
|
| Immunoblastic Lymphadenopathy | 4 | 2013 | 40 | 1.080 |
Why?
|
| Activated Protein C Resistance | 3 | 2013 | 18 | 1.070 |
Why?
|
| Proto-Oncogene Proteins c-myc | 6 | 2019 | 995 | 1.070 |
Why?
|
| Myositis, Inclusion Body | 2 | 2019 | 145 | 1.060 |
Why?
|
| Histiocytic Disorders, Malignant | 3 | 2018 | 14 | 1.000 |
Why?
|
| Factor V | 6 | 2013 | 168 | 0.980 |
Why?
|
| Partial Thromboplastin Time | 4 | 2019 | 205 | 0.960 |
Why?
|
| Plasma Cells | 5 | 2024 | 591 | 0.950 |
Why?
|
| Prothrombin Time | 2 | 2018 | 116 | 0.930 |
Why?
|
| Immunohistochemistry | 38 | 2017 | 11071 | 0.920 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 10 | 2016 | 1628 | 0.910 |
Why?
|
| Bone Marrow | 8 | 2023 | 2912 | 0.890 |
Why?
|
| Proto-Oncogene Proteins c-kit | 3 | 2014 | 727 | 0.870 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 9 | 2021 | 1547 | 0.870 |
Why?
|
| Multiple Myeloma | 14 | 2024 | 5130 | 0.870 |
Why?
|
| Lymphoma, Mantle-Cell | 3 | 2019 | 237 | 0.840 |
Why?
|
| Leukemia, Monocytic, Acute | 1 | 2022 | 58 | 0.810 |
Why?
|
| Leukemia, Hairy Cell | 2 | 2013 | 82 | 0.800 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 11 | 2021 | 1403 | 0.790 |
Why?
|
| Mast Cells | 4 | 2017 | 1390 | 0.750 |
Why?
|
| B-Lymphocytes | 14 | 2023 | 4742 | 0.720 |
Why?
|
| Leukemia, Promyelocytic, Acute | 1 | 2022 | 251 | 0.710 |
Why?
|
| Myelodysplastic Syndromes | 3 | 2019 | 1394 | 0.700 |
Why?
|
| Thymus Neoplasms | 5 | 2000 | 274 | 0.670 |
Why?
|
| Laboratories | 5 | 2021 | 462 | 0.660 |
Why?
|
| Cluster Analysis | 2 | 2016 | 2698 | 0.640 |
Why?
|
| Cell Differentiation | 11 | 2019 | 11481 | 0.630 |
Why?
|
| Leukemia, Mast-Cell | 1 | 2018 | 13 | 0.630 |
Why?
|
| Lupus Coagulation Inhibitor | 1 | 2018 | 33 | 0.620 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 2 | 2019 | 474 | 0.620 |
Why?
|
| Bone Marrow Cells | 7 | 2018 | 2414 | 0.620 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 2 | 2019 | 478 | 0.610 |
Why?
|
| Hodgkin Disease | 4 | 2019 | 1378 | 0.610 |
Why?
|
| Lectins, C-Type | 3 | 2019 | 587 | 0.610 |
Why?
|
| Precursor Cells, T-Lymphoid | 1 | 2017 | 19 | 0.580 |
Why?
|
| Thymoma | 4 | 2000 | 187 | 0.560 |
Why?
|
| Receptors, IgE | 5 | 2012 | 372 | 0.560 |
Why?
|
| Plasmacytoma | 2 | 2021 | 171 | 0.560 |
Why?
|
| Antigens, CD1d | 1 | 2017 | 217 | 0.550 |
Why?
|
| GATA3 Transcription Factor | 1 | 2017 | 152 | 0.550 |
Why?
|
| Antiphospholipid Syndrome | 1 | 2018 | 165 | 0.550 |
Why?
|
| Risk Management | 1 | 2020 | 558 | 0.540 |
Why?
|
| Leukemia, Large Granular Lymphocytic | 1 | 2016 | 24 | 0.530 |
Why?
|
| Receptors, Chemokine | 5 | 2003 | 655 | 0.530 |
Why?
|
| Histiocytosis, Langerhans-Cell | 1 | 2018 | 169 | 0.530 |
Why?
|
| T-Lymphocytes | 16 | 2017 | 10181 | 0.520 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2019 | 801 | 0.500 |
Why?
|
| Mastocytosis | 1 | 2017 | 149 | 0.500 |
Why?
|
| Malpractice | 1 | 2020 | 556 | 0.490 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 3 | 2013 | 179 | 0.490 |
Why?
|
| Th1 Cells | 4 | 2005 | 1032 | 0.490 |
Why?
|
| Pathology, Clinical | 4 | 2024 | 375 | 0.480 |
Why?
|
| Immunoenzyme Techniques | 17 | 2014 | 1705 | 0.480 |
Why?
|
| Leukemia, Myeloid, Acute | 4 | 2018 | 3602 | 0.470 |
Why?
|
| Humans | 188 | 2024 | 760621 | 0.470 |
Why?
|
| Pulmonary Fibrosis | 1 | 2018 | 506 | 0.470 |
Why?
|
| STAT3 Transcription Factor | 2 | 2018 | 877 | 0.460 |
Why?
|
| Receptors, Immunologic | 2 | 2019 | 1411 | 0.460 |
Why?
|
| Lymphoma | 5 | 2021 | 1898 | 0.440 |
Why?
|
| Genetic Diseases, Inborn | 1 | 2018 | 601 | 0.440 |
Why?
|
| Emergencies | 1 | 2020 | 1211 | 0.440 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2017 | 381 | 0.440 |
Why?
|
| Diagnosis, Differential | 12 | 2022 | 12965 | 0.430 |
Why?
|
| Ultrasonography, Doppler, Color | 1 | 2014 | 231 | 0.430 |
Why?
|
| Iodide Peroxidase | 5 | 2017 | 294 | 0.420 |
Why?
|
| Lymphoid Tissue | 3 | 2011 | 445 | 0.420 |
Why?
|
| Thigh | 1 | 2014 | 240 | 0.420 |
Why?
|
| Ascitic Fluid | 1 | 2013 | 189 | 0.420 |
Why?
|
| Anaplasma phagocytophilum | 1 | 2012 | 37 | 0.420 |
Why?
|
| Anaplasmosis | 1 | 2012 | 37 | 0.410 |
Why?
|
| Apoptosis Regulatory Proteins | 3 | 2009 | 1135 | 0.410 |
Why?
|
| Carcinoma | 6 | 2019 | 2331 | 0.410 |
Why?
|
| Pleural Effusion, Malignant | 1 | 2013 | 103 | 0.400 |
Why?
|
| Hematology | 2 | 2021 | 241 | 0.390 |
Why?
|
| Waldenstrom Macroglobulinemia | 3 | 2022 | 1067 | 0.370 |
Why?
|
| Neoplasms, Second Primary | 1 | 2019 | 1056 | 0.370 |
Why?
|
| Lymphoma, Non-Hodgkin | 5 | 2002 | 1375 | 0.370 |
Why?
|
| Granulocytes | 1 | 2012 | 551 | 0.360 |
Why?
|
| MAP Kinase Signaling System | 1 | 2018 | 1484 | 0.360 |
Why?
|
| Mediastinal Neoplasms | 2 | 2012 | 402 | 0.360 |
Why?
|
| Membrane Glycoproteins | 8 | 2008 | 3707 | 0.360 |
Why?
|
| Dendritic Cells | 6 | 2010 | 2725 | 0.360 |
Why?
|
| Leukemia, B-Cell | 1 | 2010 | 84 | 0.360 |
Why?
|
| Receptors, Tumor Necrosis Factor | 3 | 2003 | 585 | 0.350 |
Why?
|
| Histiocytes | 1 | 2010 | 98 | 0.350 |
Why?
|
| Lymphadenitis | 2 | 2006 | 98 | 0.350 |
Why?
|
| Free Tissue Flaps | 1 | 2014 | 327 | 0.340 |
Why?
|
| T-Box Domain Proteins | 6 | 2017 | 468 | 0.340 |
Why?
|
| Antigens, Differentiation, B-Lymphocyte | 2 | 2019 | 317 | 0.330 |
Why?
|
| Muscle, Skeletal | 3 | 2019 | 4925 | 0.330 |
Why?
|
| Chemokine CXCL13 | 1 | 2009 | 59 | 0.320 |
Why?
|
| Lymph Nodes | 8 | 2016 | 3486 | 0.310 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 2 | 2011 | 975 | 0.300 |
Why?
|
| Point Mutation | 2 | 2007 | 1594 | 0.300 |
Why?
|
| Transcription Factors | 9 | 2015 | 12103 | 0.300 |
Why?
|
| Protein C | 3 | 1998 | 133 | 0.300 |
Why?
|
| Polyploidy | 2 | 2012 | 119 | 0.290 |
Why?
|
| Sensitivity and Specificity | 10 | 2016 | 14660 | 0.290 |
Why?
|
| Cell Proliferation | 6 | 2016 | 10446 | 0.290 |
Why?
|
| Hematologic Neoplasms | 2 | 2023 | 1895 | 0.290 |
Why?
|
| Proto-Oncogene Proteins | 4 | 2018 | 4490 | 0.280 |
Why?
|
| Hydatidiform Mole | 3 | 2008 | 254 | 0.280 |
Why?
|
| Female | 89 | 2023 | 391270 | 0.280 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2019 | 4550 | 0.270 |
Why?
|
| Genes, myc | 1 | 2008 | 395 | 0.270 |
Why?
|
| Clone Cells | 1 | 2010 | 1660 | 0.270 |
Why?
|
| Middle Aged | 57 | 2019 | 220352 | 0.270 |
Why?
|
| Lymphoma, Extranodal NK-T-Cell | 2 | 2018 | 45 | 0.260 |
Why?
|
| Aged | 43 | 2019 | 169152 | 0.260 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 4 | 2003 | 899 | 0.260 |
Why?
|
| Receptors, Interleukin-4 | 1 | 2005 | 64 | 0.260 |
Why?
|
| Adult | 58 | 2021 | 219994 | 0.260 |
Why?
|
| Male | 77 | 2020 | 359744 | 0.260 |
Why?
|
| Erythroblasts | 2 | 2016 | 143 | 0.250 |
Why?
|
| Preoperative Care | 1 | 2014 | 2256 | 0.240 |
Why?
|
| Aged, 80 and over | 23 | 2019 | 58995 | 0.240 |
Why?
|
| Genetic Testing | 2 | 2018 | 3531 | 0.240 |
Why?
|
| Tissue Array Analysis | 1 | 2006 | 551 | 0.240 |
Why?
|
| Spleen | 6 | 2005 | 2298 | 0.230 |
Why?
|
| Splenic Diseases | 2 | 2001 | 90 | 0.230 |
Why?
|
| Emergency Service, Hospital | 10 | 2021 | 7818 | 0.230 |
Why?
|
| Lymphocyte Subsets | 1 | 2005 | 310 | 0.220 |
Why?
|
| Th2 Cells | 3 | 2003 | 1047 | 0.220 |
Why?
|
| Germinal Center | 1 | 2006 | 379 | 0.220 |
Why?
|
| Histological Techniques | 3 | 2016 | 194 | 0.220 |
Why?
|
| Thymus Gland | 4 | 2006 | 1247 | 0.220 |
Why?
|
| Neoplasm, Residual | 2 | 2021 | 1007 | 0.210 |
Why?
|
| International Normalized Ratio | 1 | 2005 | 386 | 0.210 |
Why?
|
| Herpes Simplex | 1 | 2006 | 478 | 0.210 |
Why?
|
| Nocardia Infections | 1 | 2001 | 19 | 0.200 |
Why?
|
| Gene Rearrangement | 3 | 2016 | 1122 | 0.200 |
Why?
|
| Translocation, Genetic | 3 | 2022 | 1388 | 0.190 |
Why?
|
| Leukemia, Myeloid | 2 | 2006 | 695 | 0.190 |
Why?
|
| Uterine Neoplasms | 4 | 2011 | 1439 | 0.190 |
Why?
|
| Erythrocyte Count | 2 | 2016 | 157 | 0.190 |
Why?
|
| Sickle Cell Trait | 1 | 2021 | 85 | 0.190 |
Why?
|
| Histiocytic Sarcoma | 2 | 2011 | 41 | 0.180 |
Why?
|
| Receptors, Cell Surface | 1 | 2010 | 2825 | 0.180 |
Why?
|
| Semaphorins | 2 | 1998 | 97 | 0.180 |
Why?
|
| Signal Transduction | 7 | 2018 | 23376 | 0.180 |
Why?
|
| RNA-Binding Proteins | 5 | 2004 | 1894 | 0.180 |
Why?
|
| Multigene Family | 3 | 2021 | 1077 | 0.180 |
Why?
|
| Histocompatibility Antigens Class II | 3 | 2003 | 1446 | 0.180 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 2002 | 459 | 0.180 |
Why?
|
| Gastrointestinal Neoplasms | 3 | 2014 | 951 | 0.170 |
Why?
|
| Lymphocytosis | 2 | 2016 | 119 | 0.170 |
Why?
|
| Biopsy | 7 | 2018 | 6771 | 0.170 |
Why?
|
| Protein Isoforms | 1 | 2005 | 1697 | 0.170 |
Why?
|
| DNA Nucleotidylexotransferase | 1 | 1999 | 66 | 0.170 |
Why?
|
| Spermatic Cord Torsion | 1 | 2020 | 73 | 0.170 |
Why?
|
| Oligospermia | 1 | 1999 | 59 | 0.170 |
Why?
|
| Genes, MHC Class II | 1 | 2000 | 451 | 0.170 |
Why?
|
| Neoplasm Staging | 8 | 2018 | 11152 | 0.160 |
Why?
|
| Neoplasm Proteins | 7 | 2016 | 3610 | 0.160 |
Why?
|
| Lymphoma, Follicular | 3 | 1998 | 453 | 0.160 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 4 | 2008 | 1407 | 0.160 |
Why?
|
| Heparin | 2 | 2019 | 1652 | 0.160 |
Why?
|
| beta 2-Glycoprotein I | 1 | 2018 | 28 | 0.160 |
Why?
|
| Ovum | 1 | 1999 | 187 | 0.160 |
Why?
|
| Antibodies, Anticardiolipin | 1 | 2018 | 62 | 0.160 |
Why?
|
| Predictive Value of Tests | 8 | 2017 | 15289 | 0.160 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 2 | 2018 | 368 | 0.160 |
Why?
|
| Meningitis | 1 | 2020 | 218 | 0.160 |
Why?
|
| Protein Precursors | 4 | 1992 | 1134 | 0.150 |
Why?
|
| Antigens, Neoplasm | 5 | 2006 | 1998 | 0.150 |
Why?
|
| STAT Transcription Factors | 1 | 2019 | 188 | 0.150 |
Why?
|
| Receptors, CXCR4 | 1 | 2003 | 728 | 0.150 |
Why?
|
| Contraception Behavior | 1 | 2020 | 180 | 0.150 |
Why?
|
| Adolescent | 20 | 2020 | 87810 | 0.150 |
Why?
|
| Chromosome Aberrations | 2 | 2016 | 1764 | 0.150 |
Why?
|
| Splenomegaly | 1 | 1998 | 189 | 0.150 |
Why?
|
| Data Collection | 2 | 2006 | 3315 | 0.150 |
Why?
|
| Leukemia, Myelomonocytic, Chronic | 1 | 1998 | 92 | 0.150 |
Why?
|
| Blood Coagulation Tests | 1 | 2019 | 270 | 0.150 |
Why?
|
| Thyroid Neoplasms | 3 | 2006 | 2332 | 0.150 |
Why?
|
| HLA-DR Antigens | 1 | 2019 | 630 | 0.140 |
Why?
|
| Cytoskeletal Proteins | 1 | 2003 | 1343 | 0.140 |
Why?
|
| Hematopoietic Stem Cells | 3 | 2019 | 3387 | 0.140 |
Why?
|
| Arsenicals | 1 | 2017 | 117 | 0.140 |
Why?
|
| Chemokines | 2 | 2006 | 962 | 0.140 |
Why?
|
| Clonal Anergy | 1 | 1997 | 171 | 0.140 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 1 | 2019 | 345 | 0.140 |
Why?
|
| Membrane Proteins | 4 | 2010 | 7850 | 0.140 |
Why?
|
| Lymphocyte Activation | 6 | 2007 | 5496 | 0.140 |
Why?
|
| Societies, Medical | 3 | 2024 | 3905 | 0.140 |
Why?
|
| Receptors, CXCR3 | 4 | 2003 | 238 | 0.140 |
Why?
|
| Reproducibility of Results | 10 | 2017 | 20080 | 0.140 |
Why?
|
| Receptors, OX40 | 3 | 2003 | 44 | 0.140 |
Why?
|
| Family Planning Services | 1 | 2020 | 265 | 0.140 |
Why?
|
| Fetal Hemoglobin | 2 | 2019 | 342 | 0.140 |
Why?
|
| Sulfides | 1 | 2017 | 171 | 0.140 |
Why?
|
| Zebrafish Proteins | 1 | 2003 | 1006 | 0.140 |
Why?
|
| Child | 15 | 2022 | 79806 | 0.140 |
Why?
|
| Triiodothyronine | 2 | 2017 | 493 | 0.140 |
Why?
|
| Blast Crisis | 1 | 1997 | 101 | 0.140 |
Why?
|
| Cell Adhesion Molecules | 3 | 1997 | 1602 | 0.140 |
Why?
|
| Peptides | 4 | 2018 | 4354 | 0.130 |
Why?
|
| Hemarthrosis | 1 | 1996 | 39 | 0.130 |
Why?
|
| Xenograft Model Antitumor Assays | 4 | 2018 | 3584 | 0.130 |
Why?
|
| Warfarin | 1 | 2005 | 1518 | 0.130 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2000 | 487 | 0.130 |
Why?
|
| Thyroid Gland | 2 | 2017 | 1168 | 0.130 |
Why?
|
| Point-of-Care Systems | 1 | 2005 | 1204 | 0.130 |
Why?
|
| Oxides | 1 | 2017 | 401 | 0.130 |
Why?
|
| Quality Assurance, Health Care | 1 | 2006 | 2176 | 0.130 |
Why?
|
| Neoplasms | 2 | 2016 | 22072 | 0.130 |
Why?
|
| Bone Neoplasms | 2 | 1999 | 2532 | 0.130 |
Why?
|
| Receptors, Nerve Growth Factor | 1 | 1996 | 198 | 0.130 |
Why?
|
| Spermatozoa | 1 | 1999 | 631 | 0.120 |
Why?
|
| Tissue Banks | 1 | 2016 | 184 | 0.120 |
Why?
|
| Cyclophilin A | 1 | 2015 | 58 | 0.120 |
Why?
|
| Humerus | 1 | 1997 | 269 | 0.120 |
Why?
|
| Muscle Neoplasms | 1 | 1996 | 133 | 0.120 |
Why?
|
| Enteropathy-Associated T-Cell Lymphoma | 1 | 2014 | 13 | 0.120 |
Why?
|
| Endothelins | 2 | 1992 | 127 | 0.120 |
Why?
|
| In Situ Hybridization, Fluorescence | 3 | 2016 | 2506 | 0.120 |
Why?
|
| Fertility | 1 | 1999 | 773 | 0.120 |
Why?
|
| Blood Coagulation Disorders | 1 | 1998 | 349 | 0.120 |
Why?
|
| Thyroxine | 2 | 2017 | 667 | 0.120 |
Why?
|
| Epstein-Barr Virus Infections | 2 | 2020 | 608 | 0.120 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2004 | 4353 | 0.120 |
Why?
|
| Chondrosarcoma | 1 | 1997 | 296 | 0.120 |
Why?
|
| Hemochromatosis | 1 | 1996 | 174 | 0.120 |
Why?
|
| Germ Cells | 3 | 2004 | 635 | 0.120 |
Why?
|
| Anticoagulants | 2 | 2013 | 4897 | 0.120 |
Why?
|
| Hypothyroidism | 2 | 2014 | 665 | 0.120 |
Why?
|
| Integrin alpha Chains | 1 | 2014 | 95 | 0.120 |
Why?
|
| Cell Nucleus | 3 | 2000 | 2907 | 0.120 |
Why?
|
| Phosphorylation | 2 | 2016 | 8313 | 0.120 |
Why?
|
| Gene Expression Regulation, Neoplastic | 5 | 2021 | 8515 | 0.120 |
Why?
|
| Sacrum | 1 | 1996 | 277 | 0.120 |
Why?
|
| Antibodies, Monoclonal | 9 | 2015 | 9185 | 0.110 |
Why?
|
| Endothelium, Vascular | 5 | 2003 | 4433 | 0.110 |
Why?
|
| Algorithms | 2 | 2014 | 13981 | 0.110 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2019 | 1791 | 0.110 |
Why?
|
| Mastectomy, Segmental | 1 | 2019 | 972 | 0.110 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 2 | 2003 | 1652 | 0.110 |
Why?
|
| Child, Preschool | 9 | 2020 | 42063 | 0.110 |
Why?
|
| Thrombosis | 2 | 2018 | 3052 | 0.110 |
Why?
|
| Anemia, Sickle Cell | 3 | 2019 | 1056 | 0.110 |
Why?
|
| Trans-Activators | 1 | 2003 | 2860 | 0.110 |
Why?
|
| Blood Proteins | 2 | 2013 | 1173 | 0.110 |
Why?
|
| Pain Perception | 1 | 2015 | 196 | 0.110 |
Why?
|
| Orbital Neoplasms | 2 | 2002 | 221 | 0.110 |
Why?
|
| Appendicitis | 1 | 2020 | 674 | 0.110 |
Why?
|
| Knee Joint | 3 | 1996 | 1663 | 0.110 |
Why?
|
| Paraffin Embedding | 3 | 2014 | 302 | 0.110 |
Why?
|
| Neprilysin | 3 | 2014 | 472 | 0.110 |
Why?
|
| DNA-Binding Proteins | 4 | 2006 | 9585 | 0.110 |
Why?
|
| Tumor Necrosis Factor Receptor-Associated Peptides and Proteins | 1 | 2012 | 44 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-rel | 1 | 2012 | 71 | 0.100 |
Why?
|
| Liver Regeneration | 1 | 2014 | 213 | 0.100 |
Why?
|
| Hemophilia A | 1 | 1996 | 359 | 0.100 |
Why?
|
| Cell Fractionation | 1 | 2013 | 251 | 0.100 |
Why?
|
| Antiretroviral Therapy, Highly Active | 2 | 2016 | 1894 | 0.100 |
Why?
|
| Monocytes | 4 | 2016 | 2575 | 0.100 |
Why?
|
| CD4 Lymphocyte Count | 1 | 1998 | 2569 | 0.100 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2017 | 11712 | 0.100 |
Why?
|
| Arthritis, Infectious | 1 | 1996 | 345 | 0.100 |
Why?
|
| Gene Rearrangement, B-Lymphocyte, Heavy Chain | 1 | 2012 | 91 | 0.100 |
Why?
|
| Organ Specificity | 4 | 2014 | 1955 | 0.100 |
Why?
|
| Prognosis | 7 | 2017 | 29658 | 0.100 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 1997 | 685 | 0.100 |
Why?
|
| Joint Diseases | 1 | 1996 | 457 | 0.100 |
Why?
|
| DNA Mutational Analysis | 2 | 2013 | 4107 | 0.100 |
Why?
|
| Aortic Aneurysm, Abdominal | 1 | 2001 | 1223 | 0.100 |
Why?
|
| Mice | 28 | 2021 | 81208 | 0.100 |
Why?
|
| Drug Resistance | 1 | 1998 | 1617 | 0.100 |
Why?
|
| Reference Values | 1 | 2019 | 4925 | 0.100 |
Why?
|
| CCAAT-Enhancer-Binding Protein-beta | 1 | 2011 | 102 | 0.100 |
Why?
|
| Leukemia | 2 | 2016 | 1520 | 0.090 |
Why?
|
| Gene Expression Profiling | 5 | 2016 | 9411 | 0.090 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2016 | 1110 | 0.090 |
Why?
|
| Thyroid Hormones | 1 | 2014 | 403 | 0.090 |
Why?
|
| Child Abuse | 1 | 2020 | 1067 | 0.090 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2015 | 678 | 0.090 |
Why?
|
| American Medical Association | 2 | 2021 | 60 | 0.090 |
Why?
|
| DNA | 6 | 2012 | 7233 | 0.090 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 2017 | 819 | 0.090 |
Why?
|
| Muscles | 1 | 2016 | 1581 | 0.090 |
Why?
|
| Mammary Neoplasms, Experimental | 3 | 1999 | 507 | 0.090 |
Why?
|
| T-Lymphocyte Subsets | 1 | 1999 | 1810 | 0.090 |
Why?
|
| Combined Modality Therapy | 3 | 2019 | 8552 | 0.090 |
Why?
|
| Emergency Medicine | 1 | 2020 | 1196 | 0.090 |
Why?
|
| Fetus | 3 | 2004 | 1859 | 0.090 |
Why?
|
| T-Lymphocytes, Cytotoxic | 2 | 1998 | 1765 | 0.090 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2019 | 1529 | 0.090 |
Why?
|
| Cytodiagnosis | 2 | 2013 | 442 | 0.090 |
Why?
|
| Microfluidics | 2 | 2013 | 652 | 0.090 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2019 | 3529 | 0.090 |
Why?
|
| Receptor, Notch1 | 1 | 2013 | 495 | 0.090 |
Why?
|
| Sexual Behavior | 1 | 2020 | 2086 | 0.090 |
Why?
|
| Base Sequence | 8 | 2019 | 12446 | 0.090 |
Why?
|
| Burkitt Lymphoma | 2 | 2014 | 333 | 0.090 |
Why?
|
| Thyroid Nodule | 1 | 2017 | 760 | 0.090 |
Why?
|
| Nuclear Proteins | 3 | 2019 | 5791 | 0.090 |
Why?
|
| Up-Regulation | 4 | 2014 | 4122 | 0.090 |
Why?
|
| Antigens, Surface | 4 | 2003 | 1608 | 0.090 |
Why?
|
| Gene Library | 1 | 1993 | 1060 | 0.090 |
Why?
|
| Nucleic Acid Amplification Techniques | 2 | 1989 | 330 | 0.090 |
Why?
|
| DNA-Directed DNA Polymerase | 2 | 1993 | 491 | 0.090 |
Why?
|
| Antineoplastic Agents | 7 | 2018 | 13630 | 0.090 |
Why?
|
| Hospitals | 1 | 2023 | 3928 | 0.090 |
Why?
|
| Lyme Disease | 1 | 1996 | 630 | 0.090 |
Why?
|
| Mandibular Nerve | 1 | 2009 | 59 | 0.080 |
Why?
|
| Thalidomide | 1 | 2015 | 884 | 0.080 |
Why?
|
| Molar, Third | 1 | 2009 | 53 | 0.080 |
Why?
|
| Bacteriophages | 1 | 1993 | 372 | 0.080 |
Why?
|
| Spinal Neoplasms | 1 | 1996 | 716 | 0.080 |
Why?
|
| Bacteriophage lambda | 1 | 1989 | 142 | 0.080 |
Why?
|
| Anti-HIV Agents | 2 | 2021 | 4491 | 0.080 |
Why?
|
| Blotting, Western | 4 | 2005 | 5039 | 0.080 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2014 | 611 | 0.080 |
Why?
|
| Infant | 5 | 2020 | 36060 | 0.080 |
Why?
|
| Fluorescein-5-isothiocyanate | 2 | 1999 | 222 | 0.080 |
Why?
|
| Animals | 37 | 2021 | 167963 | 0.080 |
Why?
|
| Quinazolines | 1 | 2015 | 1363 | 0.080 |
Why?
|
| Evidence-Based Medicine | 1 | 2021 | 3696 | 0.080 |
Why?
|
| Receptors, Complement 3d | 1 | 2009 | 117 | 0.080 |
Why?
|
| Phenotype | 5 | 2017 | 16546 | 0.080 |
Why?
|
| Disease Progression | 4 | 2018 | 13502 | 0.080 |
Why?
|
| Splenectomy | 2 | 2001 | 391 | 0.080 |
Why?
|
| Analgesics | 1 | 2015 | 1065 | 0.080 |
Why?
|
| Pneumonia | 1 | 2020 | 2131 | 0.080 |
Why?
|
| Vascular Surgical Procedures | 1 | 1997 | 1475 | 0.080 |
Why?
|
| Necrosis | 3 | 2014 | 1612 | 0.080 |
Why?
|
| Precancerous Conditions | 2 | 2008 | 977 | 0.080 |
Why?
|
| Frozen Sections | 2 | 2014 | 153 | 0.080 |
Why?
|
| Gastrointestinal Stromal Tumors | 1 | 2014 | 615 | 0.080 |
Why?
|
| Infant, Newborn | 3 | 2020 | 26181 | 0.080 |
Why?
|
| Gene Expression | 4 | 2008 | 7588 | 0.080 |
Why?
|
| Hepatitis C | 1 | 2018 | 1579 | 0.080 |
Why?
|
| Polymerase Chain Reaction | 4 | 2000 | 6068 | 0.080 |
Why?
|
| Alcohol-Related Disorders | 1 | 2010 | 235 | 0.070 |
Why?
|
| Skin Neoplasms | 3 | 2012 | 5799 | 0.070 |
Why?
|
| Choriocarcinoma | 1 | 2008 | 121 | 0.070 |
Why?
|
| North America | 2 | 2014 | 1284 | 0.070 |
Why?
|
| Mesothelioma | 1 | 1994 | 807 | 0.070 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2018 | 2919 | 0.070 |
Why?
|
| Young Adult | 9 | 2020 | 58741 | 0.070 |
Why?
|
| False Negative Reactions | 1 | 2008 | 573 | 0.070 |
Why?
|
| United States | 8 | 2024 | 72461 | 0.070 |
Why?
|
| Pregnancy | 10 | 2020 | 29749 | 0.070 |
Why?
|
| Cyclophosphamide | 2 | 2020 | 2221 | 0.070 |
Why?
|
| Wounds and Injuries | 1 | 2020 | 2477 | 0.070 |
Why?
|
| Hepatocytes | 1 | 2014 | 1229 | 0.070 |
Why?
|
| Cell Division | 3 | 2000 | 4463 | 0.070 |
Why?
|
| Neutrophils | 2 | 2013 | 3767 | 0.070 |
Why?
|
| Vascular Diseases | 1 | 2015 | 1182 | 0.070 |
Why?
|
| Cost-Benefit Analysis | 3 | 2021 | 5508 | 0.070 |
Why?
|
| Amino Acid Sequence | 8 | 2019 | 13451 | 0.070 |
Why?
|
| Outpatients | 1 | 2015 | 1607 | 0.070 |
Why?
|
| HIV Infections | 5 | 2021 | 17165 | 0.070 |
Why?
|
| Desmin | 2 | 1998 | 99 | 0.070 |
Why?
|
| Adolescent Behavior | 2 | 2017 | 1175 | 0.070 |
Why?
|
| Phosphatidylserines | 1 | 2007 | 188 | 0.070 |
Why?
|
| Placenta | 2 | 2008 | 1702 | 0.070 |
Why?
|
| Glycoproteins | 3 | 2006 | 2208 | 0.070 |
Why?
|
| Cell Lineage | 4 | 2016 | 2533 | 0.070 |
Why?
|
| Marijuana Smoking | 1 | 2009 | 257 | 0.070 |
Why?
|
| Blotting, Northern | 4 | 1998 | 1543 | 0.070 |
Why?
|
| False Positive Reactions | 1 | 2008 | 956 | 0.070 |
Why?
|
| Intestinal Fistula | 1 | 2007 | 143 | 0.070 |
Why?
|
| Anti-Retroviral Agents | 1 | 2016 | 1779 | 0.070 |
Why?
|
| Breast Neoplasms | 4 | 2022 | 21025 | 0.070 |
Why?
|
| Mesenchymal Stem Cells | 1 | 2016 | 1634 | 0.070 |
Why?
|
| DNA, Viral | 1 | 1993 | 2194 | 0.060 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2022 | 9276 | 0.060 |
Why?
|
| ROC Curve | 1 | 2013 | 3568 | 0.060 |
Why?
|
| Ganciclovir | 1 | 2006 | 252 | 0.060 |
Why?
|
| Antibodies, Neoplasm | 1 | 2006 | 280 | 0.060 |
Why?
|
| Herpesvirus 4, Human | 3 | 2020 | 1075 | 0.060 |
Why?
|
| Thrombocytopenia | 1 | 2013 | 1174 | 0.060 |
Why?
|
| Colonic Diseases | 1 | 2007 | 200 | 0.060 |
Why?
|
| Prospective Studies | 7 | 2016 | 54303 | 0.060 |
Why?
|
| Psychometrics | 1 | 2015 | 3051 | 0.060 |
Why?
|
| Sequence Homology, Nucleic Acid | 2 | 1999 | 1055 | 0.060 |
Why?
|
| MicroRNAs | 1 | 2021 | 3790 | 0.060 |
Why?
|
| Health Promotion | 1 | 2017 | 2206 | 0.060 |
Why?
|
| Mandible | 1 | 2009 | 750 | 0.060 |
Why?
|
| Interleukin-13 | 1 | 2007 | 371 | 0.060 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2020 | 5649 | 0.060 |
Why?
|
| Molecular Sequence Data | 8 | 2004 | 17624 | 0.060 |
Why?
|
| Choristoma | 1 | 2006 | 207 | 0.060 |
Why?
|
| Pain Measurement | 1 | 2015 | 3528 | 0.060 |
Why?
|
| beta Catenin | 2 | 2015 | 1043 | 0.060 |
Why?
|
| Neuritis | 1 | 2004 | 36 | 0.060 |
Why?
|
| Cell Line, Tumor | 5 | 2017 | 16939 | 0.060 |
Why?
|
| Intestinal Neoplasms | 1 | 2007 | 311 | 0.060 |
Why?
|
| Palatine Tonsil | 1 | 2005 | 193 | 0.060 |
Why?
|
| Ultrasonography | 1 | 2017 | 5961 | 0.060 |
Why?
|
| Cyclins | 1 | 2006 | 593 | 0.060 |
Why?
|
| Receptors, Virus | 1 | 2007 | 639 | 0.060 |
Why?
|
| Protein-Tyrosine Kinases | 3 | 2003 | 2418 | 0.060 |
Why?
|
| Head and Neck Neoplasms | 1 | 1998 | 2882 | 0.060 |
Why?
|
| Myocardium | 1 | 2017 | 4700 | 0.060 |
Why?
|
| Morbidity | 2 | 2021 | 1765 | 0.060 |
Why?
|
| Patient Education as Topic | 2 | 2015 | 2315 | 0.060 |
Why?
|
| Age Factors | 2 | 2020 | 18416 | 0.060 |
Why?
|
| Genetic Association Studies | 1 | 2013 | 2717 | 0.060 |
Why?
|
| Antigens, CD19 | 2 | 2014 | 424 | 0.060 |
Why?
|
| Liver | 2 | 2014 | 7509 | 0.060 |
Why?
|
| Recurrence | 5 | 2014 | 8482 | 0.060 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2006 | 629 | 0.060 |
Why?
|
| Cerebrospinal Fluid | 2 | 2004 | 544 | 0.060 |
Why?
|
| Listeriosis | 1 | 2004 | 148 | 0.060 |
Why?
|
| Immunity, Innate | 2 | 2007 | 3047 | 0.060 |
Why?
|
| Arthritis, Experimental | 1 | 2006 | 291 | 0.060 |
Why?
|
| Vincristine | 1 | 2006 | 1039 | 0.060 |
Why?
|
| Oxazines | 1 | 2005 | 341 | 0.050 |
Why?
|
| Transfection | 5 | 1999 | 5781 | 0.050 |
Why?
|
| Mouth Neoplasms | 1 | 2008 | 593 | 0.050 |
Why?
|
| Hematologic Tests | 1 | 2004 | 238 | 0.050 |
Why?
|
| Receptor-Like Protein Tyrosine Phosphatases, Class 3 | 1 | 2002 | 24 | 0.050 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2006 | 693 | 0.050 |
Why?
|
| Interviews as Topic | 1 | 2010 | 2659 | 0.050 |
Why?
|
| Lymphoid Enhancer-Binding Factor 1 | 1 | 2003 | 84 | 0.050 |
Why?
|
| Macrophage Inflammatory Proteins | 1 | 2002 | 121 | 0.050 |
Why?
|
| T Cell Transcription Factor 1 | 1 | 2003 | 67 | 0.050 |
Why?
|
| Polyneuropathies | 1 | 2004 | 137 | 0.050 |
Why?
|
| Chemokine CCL20 | 1 | 2002 | 63 | 0.050 |
Why?
|
| Retrospective Studies | 9 | 2023 | 80372 | 0.050 |
Why?
|
| Receptors, CCR6 | 1 | 2002 | 73 | 0.050 |
Why?
|
| Mass Screening | 1 | 2018 | 5423 | 0.050 |
Why?
|
| Pediatrics | 2 | 2012 | 3586 | 0.050 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2005 | 618 | 0.050 |
Why?
|
| Endothelin-1 | 4 | 1992 | 302 | 0.050 |
Why?
|
| Drug Prescriptions | 1 | 2012 | 1673 | 0.050 |
Why?
|
| Lymphopoiesis | 1 | 2023 | 133 | 0.050 |
Why?
|
| Cross-Sectional Studies | 4 | 2020 | 25942 | 0.050 |
Why?
|
| Alleles | 1 | 2013 | 6898 | 0.050 |
Why?
|
| Fibromatosis, Abdominal | 1 | 2001 | 21 | 0.050 |
Why?
|
| Quality Control | 1 | 2005 | 828 | 0.050 |
Why?
|
| Nocardia | 1 | 2001 | 9 | 0.050 |
Why?
|
| Genotype | 2 | 2013 | 12960 | 0.050 |
Why?
|
| Epigenesis, Genetic | 1 | 2015 | 3758 | 0.050 |
Why?
|
| Genetic Vectors | 3 | 1999 | 3380 | 0.050 |
Why?
|
| Phagocytosis | 1 | 2007 | 1535 | 0.050 |
Why?
|
| RNA Splicing | 2 | 2023 | 915 | 0.050 |
Why?
|
| Chemokines, CC | 1 | 2002 | 283 | 0.050 |
Why?
|
| Genes, Immunoglobulin | 1 | 2002 | 285 | 0.050 |
Why?
|
| Mice, Knockout | 5 | 2014 | 14372 | 0.050 |
Why?
|
| Tumor Microenvironment | 3 | 2022 | 3844 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2000 | 36290 | 0.050 |
Why?
|
| Immunoglobulin G | 1 | 2013 | 4541 | 0.050 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2002 | 2828 | 0.050 |
Why?
|
| Central Nervous System Diseases | 1 | 2005 | 521 | 0.050 |
Why?
|
| DNA, Recombinant | 4 | 1993 | 455 | 0.050 |
Why?
|
| Testis | 2 | 2004 | 794 | 0.050 |
Why?
|
| Cytochrome b Group | 2 | 1991 | 59 | 0.050 |
Why?
|
| RNA, Messenger | 8 | 2015 | 12766 | 0.050 |
Why?
|
| Nebulizers and Vaporizers | 1 | 2001 | 137 | 0.050 |
Why?
|
| Granuloma, Plasma Cell | 1 | 2001 | 80 | 0.050 |
Why?
|
| Vascular Neoplasms | 1 | 2002 | 167 | 0.050 |
Why?
|
| Ankle | 1 | 2004 | 350 | 0.050 |
Why?
|
| Homovanillic Acid | 1 | 2000 | 75 | 0.050 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2006 | 749 | 0.050 |
Why?
|
| Tumor Cells, Cultured | 5 | 2017 | 6131 | 0.050 |
Why?
|
| Radiography | 3 | 1996 | 6965 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 13 | 1 | 2021 | 193 | 0.050 |
Why?
|
| RNA | 3 | 2023 | 2722 | 0.040 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2002 | 418 | 0.040 |
Why?
|
| Thromboembolism | 1 | 2007 | 1017 | 0.040 |
Why?
|
| Stem Cells | 2 | 2004 | 3523 | 0.040 |
Why?
|
| Contraceptive Devices | 1 | 2020 | 24 | 0.040 |
Why?
|
| Receptors, CCR4 | 1 | 2000 | 77 | 0.040 |
Why?
|
| Pain | 1 | 2015 | 5066 | 0.040 |
Why?
|
| Models, Biological | 1 | 2016 | 9467 | 0.040 |
Why?
|
| Trypanosoma brucei brucei | 3 | 1985 | 45 | 0.040 |
Why?
|
| Quality Improvement | 1 | 2015 | 3836 | 0.040 |
Why?
|
| Ileum | 1 | 2002 | 555 | 0.040 |
Why?
|
| Post-Exposure Prophylaxis | 1 | 2021 | 108 | 0.040 |
Why?
|
| Leukocyte Count | 1 | 2004 | 1600 | 0.040 |
Why?
|
| Apoptosis | 4 | 2017 | 9501 | 0.040 |
Why?
|
| Lymphatic Diseases | 1 | 2001 | 319 | 0.040 |
Why?
|
| Platelet Transfusion | 1 | 2003 | 294 | 0.040 |
Why?
|
| Medication Adherence | 1 | 2012 | 2165 | 0.040 |
Why?
|
| Reference Standards | 2 | 2004 | 1004 | 0.040 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 2002 | 663 | 0.040 |
Why?
|
| Cytogenetics | 1 | 2000 | 198 | 0.040 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 1993 | 3075 | 0.040 |
Why?
|
| Receptors, CXCR5 | 1 | 2000 | 88 | 0.040 |
Why?
|
| Interferon-gamma | 3 | 2015 | 3157 | 0.040 |
Why?
|
| Chemokine CXCL9 | 1 | 2000 | 135 | 0.040 |
Why?
|
| Carrier Proteins | 3 | 2019 | 4938 | 0.040 |
Why?
|
| Logistic Models | 1 | 2014 | 13314 | 0.040 |
Why?
|
| Molecular Biology | 1 | 2023 | 580 | 0.040 |
Why?
|
| Caregivers | 1 | 2012 | 2224 | 0.040 |
Why?
|
| Anaplasia | 1 | 1999 | 16 | 0.040 |
Why?
|
| Ribosomal Proteins | 1 | 2001 | 363 | 0.040 |
Why?
|
| Genetic Code | 1 | 1999 | 138 | 0.040 |
Why?
|
| Thiazolidinediones | 1 | 2002 | 465 | 0.040 |
Why?
|
| Hemoglobins | 1 | 2005 | 1521 | 0.040 |
Why?
|
| Mycosis Fungoides | 1 | 2001 | 168 | 0.040 |
Why?
|
| Doxorubicin | 1 | 2006 | 2209 | 0.040 |
Why?
|
| Staining and Labeling | 2 | 2006 | 1089 | 0.040 |
Why?
|
| Analgesics, Opioid | 1 | 2015 | 3763 | 0.040 |
Why?
|
| Antifibrinolytic Agents | 1 | 2002 | 292 | 0.040 |
Why?
|
| Isoantibodies | 1 | 2003 | 661 | 0.040 |
Why?
|
| Skin | 2 | 2007 | 4466 | 0.040 |
Why?
|
| Receptors, Cytokine | 1 | 2000 | 258 | 0.040 |
Why?
|
| Uterus | 1 | 2003 | 651 | 0.040 |
Why?
|
| Wnt Proteins | 1 | 2003 | 719 | 0.040 |
Why?
|
| Mood Disorders | 1 | 2005 | 1124 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2022 | 346 | 0.040 |
Why?
|
| Acute Disease | 4 | 2006 | 7269 | 0.040 |
Why?
|
| Imidazolines | 1 | 2018 | 18 | 0.040 |
Why?
|
| Hospitals, Urban | 2 | 2012 | 499 | 0.040 |
Why?
|
| Opportunistic Infections | 1 | 2001 | 377 | 0.040 |
Why?
|
| Sulfonamides | 1 | 2008 | 1977 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 1999 | 315 | 0.040 |
Why?
|
| Contraceptive Agents | 1 | 2020 | 145 | 0.040 |
Why?
|
| Myeloid Differentiation Factor 88 | 1 | 2023 | 581 | 0.040 |
Why?
|
| Dexamethasone | 1 | 2006 | 1927 | 0.040 |
Why?
|
| gamma-Globins | 1 | 2019 | 96 | 0.040 |
Why?
|
| Boston | 3 | 2012 | 9280 | 0.040 |
Why?
|
| Cadherins | 1 | 2003 | 898 | 0.040 |
Why?
|
| Tissue Distribution | 1 | 2002 | 2262 | 0.040 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2008 | 4024 | 0.040 |
Why?
|
| Erythroid Precursor Cells | 1 | 2019 | 211 | 0.040 |
Why?
|
| Hepatitis C Antibodies | 1 | 2018 | 145 | 0.040 |
Why?
|
| Pregnancy in Adolescence | 1 | 2020 | 162 | 0.040 |
Why?
|
| Bronchodilator Agents | 1 | 2001 | 506 | 0.040 |
Why?
|
| Immunologic Memory | 2 | 2002 | 1354 | 0.040 |
Why?
|
| Chromosome Disorders | 1 | 2021 | 499 | 0.040 |
Why?
|
| Chemokines, CXC | 1 | 2000 | 421 | 0.040 |
Why?
|
| Receptors, CCR5 | 1 | 2000 | 488 | 0.040 |
Why?
|
| Pyrazoles | 1 | 2008 | 1999 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2022 | 556 | 0.040 |
Why?
|
| Case-Control Studies | 1 | 2016 | 22053 | 0.040 |
Why?
|
| INDEL Mutation | 1 | 2019 | 266 | 0.040 |
Why?
|
| Chronic Disease | 3 | 1999 | 9287 | 0.040 |
Why?
|
| Infusion Pumps | 1 | 2019 | 163 | 0.040 |
Why?
|
| Education | 1 | 2021 | 534 | 0.040 |
Why?
|
| Mice, Inbred BALB C | 5 | 2007 | 6216 | 0.040 |
Why?
|
| Depsipeptides | 1 | 2018 | 95 | 0.040 |
Why?
|
| Genes, bcl-2 | 1 | 1998 | 119 | 0.040 |
Why?
|
| Alternative Splicing | 1 | 2023 | 1091 | 0.040 |
Why?
|
| Venous Thrombosis | 1 | 2007 | 1299 | 0.040 |
Why?
|
| Accreditation | 1 | 2021 | 477 | 0.040 |
Why?
|
| Histocompatibility Antigens | 2 | 2015 | 467 | 0.040 |
Why?
|
| Color | 1 | 1998 | 298 | 0.040 |
Why?
|
| Leukemic Infiltration | 1 | 1997 | 47 | 0.040 |
Why?
|
| Pemphigoid, Benign Mucous Membrane | 1 | 1998 | 115 | 0.040 |
Why?
|
| Lymphocyte Culture Test, Mixed | 1 | 1997 | 516 | 0.040 |
Why?
|
| Lymphocyte Depletion | 1 | 1999 | 602 | 0.040 |
Why?
|
| Mice, SCID | 2 | 2017 | 2627 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2014 | 17790 | 0.040 |
Why?
|
| Conjunctivitis | 1 | 1998 | 155 | 0.030 |
Why?
|
| Autoimmune Diseases | 2 | 2000 | 2250 | 0.030 |
Why?
|
| Escherichia coli | 1 | 1989 | 4219 | 0.030 |
Why?
|
| Ikaros Transcription Factor | 1 | 2018 | 231 | 0.030 |
Why?
|
| beta-Thalassemia | 1 | 2019 | 235 | 0.030 |
Why?
|
| Mutation | 5 | 2013 | 29932 | 0.030 |
Why?
|
| Karyotyping | 1 | 1998 | 1171 | 0.030 |
Why?
|
| Chromosome Mapping | 3 | 2004 | 4625 | 0.030 |
Why?
|
| Contraception | 1 | 2020 | 349 | 0.030 |
Why?
|
| Epithelium | 2 | 1998 | 1605 | 0.030 |
Why?
|
| Evidence-Based Practice | 1 | 2021 | 496 | 0.030 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 2 | 2001 | 1613 | 0.030 |
Why?
|
| Chromosome Deletion | 1 | 2021 | 1387 | 0.030 |
Why?
|
| Cytokines | 4 | 2007 | 7343 | 0.030 |
Why?
|
| Pulmonary Embolism | 2 | 2002 | 2543 | 0.030 |
Why?
|
| Specimen Handling | 1 | 2021 | 707 | 0.030 |
Why?
|
| Receptor, erbB-2 | 1 | 2006 | 2554 | 0.030 |
Why?
|
| Cytoplasm | 1 | 2000 | 1516 | 0.030 |
Why?
|
| Pre-Eclampsia | 1 | 2005 | 1229 | 0.030 |
Why?
|
| Leukemia, Experimental | 1 | 2016 | 225 | 0.030 |
Why?
|
| Adenocarcinoma, Clear Cell | 1 | 1997 | 217 | 0.030 |
Why?
|
| Thrombophlebitis | 1 | 1996 | 288 | 0.030 |
Why?
|
| Adipocytes | 1 | 2002 | 1179 | 0.030 |
Why?
|
| Automation, Laboratory | 1 | 2016 | 103 | 0.030 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 1999 | 1126 | 0.030 |
Why?
|
| Tissue Fixation | 1 | 1996 | 241 | 0.030 |
Why?
|
| Peroxidase | 1 | 1998 | 605 | 0.030 |
Why?
|
| Antigen-Presenting Cells | 2 | 2015 | 967 | 0.030 |
Why?
|
| Preventive Medicine | 1 | 2017 | 250 | 0.030 |
Why?
|
| Molecular Targeted Therapy | 2 | 2017 | 2803 | 0.030 |
Why?
|
| Neoplasm Transplantation | 2 | 2016 | 2014 | 0.030 |
Why?
|
| Neuropsychological Tests | 2 | 2016 | 7021 | 0.030 |
Why?
|
| Abdominal Pain | 1 | 2001 | 1063 | 0.030 |
Why?
|
| Thiazoles | 1 | 2002 | 1511 | 0.030 |
Why?
|
| Interleukin-4 | 1 | 1999 | 1130 | 0.030 |
Why?
|
| Janus Kinase 2 | 1 | 2018 | 542 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2013 | 3804 | 0.030 |
Why?
|
| Diagnostic Errors | 1 | 2002 | 1266 | 0.030 |
Why?
|
| Fusion Proteins, bcr-abl | 1 | 1997 | 431 | 0.030 |
Why?
|
| Cell Cycle | 2 | 2017 | 2934 | 0.030 |
Why?
|
| Postoperative Complications | 1 | 1997 | 15697 | 0.030 |
Why?
|
| Carbon Tetrachloride | 1 | 2014 | 72 | 0.030 |
Why?
|
| Isoquinolines | 1 | 2016 | 353 | 0.030 |
Why?
|
| Toxins, Biological | 1 | 2014 | 61 | 0.030 |
Why?
|
| Pregnancy Complications, Hematologic | 1 | 1996 | 177 | 0.030 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2016 | 223 | 0.030 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 1998 | 646 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 1 | 2012 | 7408 | 0.030 |
Why?
|
| mRNA Cleavage and Polyadenylation Factors | 1 | 2014 | 105 | 0.030 |
Why?
|
| Colitis | 1 | 2002 | 1229 | 0.030 |
Why?
|
| Wrist Joint | 1 | 1996 | 265 | 0.030 |
Why?
|
| CD4-CD8 Ratio | 1 | 1993 | 114 | 0.030 |
Why?
|
| Erythroid Cells | 1 | 2015 | 235 | 0.030 |
Why?
|
| Administration, Intranasal | 1 | 2015 | 471 | 0.030 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2020 | 3986 | 0.030 |
Why?
|
| Contraceptives, Oral | 1 | 1996 | 554 | 0.030 |
Why?
|
| HIV | 1 | 2021 | 1579 | 0.030 |
Why?
|
| Disease Models, Animal | 2 | 2017 | 18137 | 0.030 |
Why?
|
| Genes, p53 | 1 | 2016 | 713 | 0.030 |
Why?
|
| Graft Occlusion, Vascular | 1 | 1997 | 560 | 0.030 |
Why?
|
| Cells, Cultured | 5 | 2013 | 18957 | 0.030 |
Why?
|
| Antiviral Agents | 1 | 2006 | 3061 | 0.030 |
Why?
|
| Gene Deletion | 1 | 2021 | 2668 | 0.030 |
Why?
|
| Taq Polymerase | 1 | 1993 | 20 | 0.030 |
Why?
|
| Proteins | 3 | 2003 | 6029 | 0.030 |
Why?
|
| Macrophages | 5 | 2007 | 5745 | 0.030 |
Why?
|
| Stem Cell Niche | 1 | 2016 | 346 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 4 | 2021 | 22023 | 0.030 |
Why?
|
| Vimentin | 1 | 1994 | 255 | 0.030 |
Why?
|
| Injections, Intravenous | 1 | 2015 | 1385 | 0.030 |
Why?
|
| Antigens, CD20 | 1 | 2014 | 201 | 0.030 |
Why?
|
| Platelet Factor 4 | 1 | 2013 | 129 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 4 | 1992 | 5785 | 0.030 |
Why?
|
| Vasculitis | 1 | 1997 | 523 | 0.030 |
Why?
|
| Statistics as Topic | 1 | 1999 | 2362 | 0.030 |
Why?
|
| Electrophoresis, Agar Gel | 1 | 1993 | 217 | 0.030 |
Why?
|
| Synovial Membrane | 1 | 1996 | 524 | 0.030 |
Why?
|
| Cell Separation | 1 | 1998 | 1720 | 0.030 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2018 | 1347 | 0.030 |
Why?
|
| Neoplastic Stem Cells | 2 | 2017 | 1347 | 0.030 |
Why?
|
| Stromal Cells | 1 | 1998 | 1326 | 0.030 |
Why?
|
| Coculture Techniques | 1 | 2016 | 1342 | 0.030 |
Why?
|
| Oligonucleotide Probes | 1 | 1993 | 418 | 0.030 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 1 | 2014 | 367 | 0.030 |
Why?
|
| Dimethylformamide | 1 | 1992 | 20 | 0.030 |
Why?
|
| Remission Induction | 1 | 2018 | 2392 | 0.030 |
Why?
|
| Fentanyl | 1 | 2015 | 434 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 1999 | 4573 | 0.030 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2019 | 1356 | 0.030 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2002 | 3765 | 0.030 |
Why?
|
| Cell Death | 1 | 2017 | 1672 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 1997 | 1832 | 0.020 |
Why?
|
| Program Development | 1 | 2018 | 1297 | 0.020 |
Why?
|
| Indicators and Reagents | 1 | 1993 | 461 | 0.020 |
Why?
|
| Interleukin-2 | 1 | 1999 | 1889 | 0.020 |
Why?
|
| Plasmids | 3 | 1992 | 2275 | 0.020 |
Why?
|
| Mice, Inbred NOD | 1 | 2016 | 1837 | 0.020 |
Why?
|
| Leukocytes, Mononuclear | 1 | 1998 | 1827 | 0.020 |
Why?
|
| Random Allocation | 1 | 2016 | 2394 | 0.020 |
Why?
|
| Groin | 1 | 2011 | 107 | 0.020 |
Why?
|
| GATA2 Transcription Factor | 1 | 1992 | 158 | 0.020 |
Why?
|
| Transcription, Genetic | 5 | 1996 | 7593 | 0.020 |
Why?
|
| Risk-Taking | 1 | 2017 | 998 | 0.020 |
Why?
|
| Epitopes | 1 | 1998 | 2503 | 0.020 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 1993 | 778 | 0.020 |
Why?
|
| Biopsy, Needle | 1 | 1996 | 1630 | 0.020 |
Why?
|
| Radiography, Abdominal | 1 | 2014 | 532 | 0.020 |
Why?
|
| Prescription Fees | 1 | 2012 | 151 | 0.020 |
Why?
|
| Viral Proteins | 1 | 1998 | 1802 | 0.020 |
Why?
|
| Microscopy, Electron | 1 | 1994 | 2558 | 0.020 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 1997 | 800 | 0.020 |
Why?
|
| Protein Binding | 2 | 2018 | 9335 | 0.020 |
Why?
|
| Sampling Studies | 1 | 2012 | 613 | 0.020 |
Why?
|
| Anatomy, Regional | 1 | 2009 | 4 | 0.020 |
Why?
|
| Mice, Transgenic | 4 | 2017 | 9530 | 0.020 |
Why?
|
| Maxillary Artery | 1 | 2009 | 18 | 0.020 |
Why?
|
| Hospitals, University | 1 | 2012 | 568 | 0.020 |
Why?
|
| Cloning, Molecular | 4 | 1996 | 4169 | 0.020 |
Why?
|
| Pelvic Neoplasms | 1 | 2011 | 248 | 0.020 |
Why?
|
| Bone Marrow Transplantation | 1 | 1997 | 2693 | 0.020 |
Why?
|
| Anatomy, Cross-Sectional | 1 | 2009 | 141 | 0.020 |
Why?
|
| Prevalence | 2 | 2016 | 15687 | 0.020 |
Why?
|
| Genes | 2 | 1984 | 1845 | 0.020 |
Why?
|
| Hip Joint | 1 | 1996 | 1006 | 0.020 |
Why?
|
| Cell Movement | 2 | 2015 | 5206 | 0.020 |
Why?
|
| Axilla | 1 | 2011 | 626 | 0.020 |
Why?
|
| Directive Counseling | 1 | 2010 | 171 | 0.020 |
Why?
|
| Cattle | 2 | 1992 | 3847 | 0.020 |
Why?
|
| Disease-Free Survival | 2 | 2014 | 6828 | 0.020 |
Why?
|
| Kidney Glomerulus | 1 | 1991 | 568 | 0.020 |
Why?
|
| Tretinoin | 1 | 1992 | 519 | 0.020 |
Why?
|
| Regression Analysis | 1 | 1998 | 6360 | 0.020 |
Why?
|
| Multiprotein Complexes | 1 | 2015 | 1120 | 0.020 |
Why?
|
| Radiography, Interventional | 1 | 1996 | 1114 | 0.020 |
Why?
|
| Oncogene Protein v-akt | 1 | 2008 | 129 | 0.020 |
Why?
|
| RNA Caps | 2 | 1985 | 73 | 0.020 |
Why?
|
| HeLa Cells | 2 | 1992 | 3105 | 0.020 |
Why?
|
| Skin Diseases | 1 | 1997 | 1089 | 0.020 |
Why?
|
| Triage | 1 | 2015 | 987 | 0.020 |
Why?
|
| Follow-Up Studies | 3 | 2021 | 39261 | 0.020 |
Why?
|
| Communication Barriers | 1 | 2012 | 415 | 0.020 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 2011 | 329 | 0.020 |
Why?
|
| Neuralgia | 1 | 2015 | 600 | 0.020 |
Why?
|
| Chorionic Gonadotropin, beta Subunit, Human | 1 | 2008 | 81 | 0.020 |
Why?
|
| Neck | 1 | 1993 | 731 | 0.020 |
Why?
|
| Repressor Proteins | 1 | 2019 | 2981 | 0.020 |
Why?
|
| Fibroblasts | 1 | 1998 | 4090 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 1999 | 4357 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2015 | 4899 | 0.020 |
Why?
|
| Receptors, Granulocyte Colony-Stimulating Factor | 1 | 2006 | 21 | 0.020 |
Why?
|
| Telephone | 1 | 2010 | 624 | 0.020 |
Why?
|
| Trust | 1 | 2012 | 532 | 0.020 |
Why?
|
| Cyclin D3 | 1 | 2006 | 54 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2013 | 3615 | 0.020 |
Why?
|
| Transplantation, Autologous | 1 | 2011 | 2116 | 0.020 |
Why?
|
| Cell Cycle Proteins | 1 | 2018 | 3446 | 0.020 |
Why?
|
| Sclerosis | 1 | 2007 | 210 | 0.020 |
Why?
|
| Actins | 1 | 1994 | 2049 | 0.020 |
Why?
|
| Low Back Pain | 1 | 2015 | 979 | 0.020 |
Why?
|
| Ki-67 Antigen | 1 | 2008 | 631 | 0.020 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2014 | 1596 | 0.020 |
Why?
|
| Drug Delivery Systems | 1 | 2017 | 2221 | 0.020 |
Why?
|
| Genes, erbB-2 | 1 | 2006 | 162 | 0.020 |
Why?
|
| NIH 3T3 Cells | 1 | 2007 | 670 | 0.020 |
Why?
|
| Cyclooxygenase 2 | 1 | 2008 | 599 | 0.020 |
Why?
|
| Proteome | 1 | 2016 | 1855 | 0.020 |
Why?
|
| Hysterectomy | 1 | 2011 | 904 | 0.020 |
Why?
|
| Cohort Studies | 3 | 2013 | 41335 | 0.020 |
Why?
|
| Nanoparticles | 1 | 2017 | 1943 | 0.020 |
Why?
|
| Bleomycin | 1 | 2007 | 495 | 0.020 |
Why?
|
| Time Factors | 2 | 2015 | 40165 | 0.020 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2008 | 255 | 0.020 |
Why?
|
| Pilot Projects | 2 | 2009 | 8555 | 0.020 |
Why?
|
| Ligands | 2 | 2003 | 3276 | 0.020 |
Why?
|
| Transcriptional Activation | 1 | 1992 | 1755 | 0.020 |
Why?
|
| Dinoprostone | 1 | 2008 | 598 | 0.020 |
Why?
|
| Radiotherapy Dosage | 1 | 2012 | 2897 | 0.020 |
Why?
|
| Radiotherapy | 1 | 2012 | 1504 | 0.020 |
Why?
|
| Risk Factors | 5 | 2018 | 74359 | 0.020 |
Why?
|
| Piperazines | 1 | 2016 | 2525 | 0.020 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2022 | 5643 | 0.020 |
Why?
|
| Lymph Node Excision | 1 | 2011 | 1303 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2017 | 10827 | 0.020 |
Why?
|
| Pregnancy Trimester, Second | 1 | 2008 | 732 | 0.020 |
Why?
|
| Carcinoembryonic Antigen | 1 | 2006 | 336 | 0.020 |
Why?
|
| Cell Line | 3 | 2012 | 15620 | 0.020 |
Why?
|
| Keratins | 1 | 2006 | 497 | 0.020 |
Why?
|
| Alkynes | 1 | 2005 | 313 | 0.020 |
Why?
|
| Autoanalysis | 1 | 2004 | 71 | 0.010 |
Why?
|
| Down-Regulation | 1 | 2011 | 2913 | 0.010 |
Why?
|
| Histocompatibility Antigens Class I | 2 | 2003 | 1355 | 0.010 |
Why?
|
| Qualitative Research | 1 | 2015 | 2963 | 0.010 |
Why?
|
| Trypanosoma | 1 | 1984 | 16 | 0.010 |
Why?
|
| Cyclopropanes | 1 | 2005 | 431 | 0.010 |
Why?
|
| Benzoxazines | 1 | 2005 | 309 | 0.010 |
Why?
|
| Educational Status | 1 | 2012 | 2515 | 0.010 |
Why?
|
| Sural Nerve | 1 | 2004 | 105 | 0.010 |
Why?
|
| RNA, Ribosomal | 1 | 1985 | 226 | 0.010 |
Why?
|
| Binding Sites | 1 | 2012 | 6048 | 0.010 |
Why?
|
| Recovery of Function | 1 | 2014 | 2985 | 0.010 |
Why?
|
| Internet | 1 | 2016 | 3078 | 0.010 |
Why?
|
| Protein Array Analysis | 1 | 2005 | 401 | 0.010 |
Why?
|
| Cytotoxicity, Immunologic | 2 | 1999 | 1351 | 0.010 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2014 | 6544 | 0.010 |
Why?
|
| Mice, Inbred C3H | 1 | 2004 | 915 | 0.010 |
Why?
|
| Adoptive Transfer | 1 | 2006 | 822 | 0.010 |
Why?
|
| Two-Hybrid System Techniques | 1 | 2004 | 458 | 0.010 |
Why?
|
| Neuroblastoma | 1 | 1991 | 1252 | 0.010 |
Why?
|
| Stem Cell Transplantation | 1 | 2011 | 1599 | 0.010 |
Why?
|
| Transplantation, Homologous | 1 | 2011 | 4810 | 0.010 |
Why?
|
| Scleroderma, Systemic | 1 | 2007 | 344 | 0.010 |
Why?
|
| Propylthiouracil | 1 | 2002 | 68 | 0.010 |
Why?
|
| Treatment Outcome | 4 | 2014 | 65017 | 0.010 |
Why?
|
| Phagocytes | 1 | 2004 | 296 | 0.010 |
Why?
|
| HIV-1 | 1 | 2000 | 6849 | 0.010 |
Why?
|
| Asthma | 1 | 2001 | 6172 | 0.010 |
Why?
|
| Listeria monocytogenes | 1 | 2004 | 248 | 0.010 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p57 | 1 | 2002 | 43 | 0.010 |
Why?
|
| Chromans | 1 | 2002 | 117 | 0.010 |
Why?
|
| Disease Management | 1 | 2013 | 2514 | 0.010 |
Why?
|
| Phosphorylcholine | 1 | 2002 | 153 | 0.010 |
Why?
|
| Zinc Fingers | 1 | 2004 | 568 | 0.010 |
Why?
|
| Ploidies | 1 | 2002 | 275 | 0.010 |
Why?
|
| Umbilical Cord | 1 | 2003 | 181 | 0.010 |
Why?
|
| Macrophage Activation | 1 | 2004 | 554 | 0.010 |
Why?
|
| Immune System | 1 | 2007 | 798 | 0.010 |
Why?
|
| Binding, Competitive | 1 | 2003 | 1142 | 0.010 |
Why?
|
| Urban Population | 1 | 2009 | 2022 | 0.010 |
Why?
|
| Pandemics | 1 | 2021 | 8624 | 0.010 |
Why?
|
| Conjunctival Neoplasms | 1 | 2002 | 77 | 0.010 |
Why?
|
| Neutropenia | 1 | 2006 | 884 | 0.010 |
Why?
|
| Gene Rearrangement, T-Lymphocyte | 1 | 2001 | 111 | 0.010 |
Why?
|
| Simian virus 40 | 2 | 1991 | 291 | 0.010 |
Why?
|
| Immunoglobulin Fab Fragments | 1 | 2003 | 465 | 0.010 |
Why?
|
| Phosphatidylcholines | 1 | 2002 | 406 | 0.010 |
Why?
|
| 3T3 Cells | 1 | 2002 | 1085 | 0.010 |
Why?
|
| Neurologic Examination | 1 | 2004 | 916 | 0.010 |
Why?
|
| DNA, Neoplasm | 2 | 2000 | 1745 | 0.010 |
Why?
|
| Motivation | 1 | 2010 | 1993 | 0.010 |
Why?
|
| Parotid Neoplasms | 1 | 2002 | 157 | 0.010 |
Why?
|
| Genomic Imprinting | 1 | 2002 | 330 | 0.010 |
Why?
|
| Herpesviridae Infections | 1 | 2001 | 270 | 0.010 |
Why?
|
| Endometrium | 1 | 2003 | 403 | 0.010 |
Why?
|
| Research Design | 1 | 2016 | 6180 | 0.010 |
Why?
|
| Poverty | 1 | 2012 | 2695 | 0.010 |
Why?
|
| Liposarcoma | 1 | 2002 | 283 | 0.010 |
Why?
|
| Herpesvirus 8, Human | 1 | 2001 | 255 | 0.010 |
Why?
|
| Sequence Alignment | 1 | 2004 | 2176 | 0.010 |
Why?
|
| Fibrosis | 1 | 2007 | 2042 | 0.010 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2000 | 613 | 0.010 |
Why?
|
| Disease Susceptibility | 1 | 2006 | 1791 | 0.010 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2014 | 5253 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2016 | 10344 | 0.010 |
Why?
|
| Colonoscopy | 1 | 2007 | 1387 | 0.010 |
Why?
|
| Meiosis | 1 | 2000 | 328 | 0.010 |
Why?
|
| Physician-Patient Relations | 1 | 2012 | 3242 | 0.010 |
Why?
|
| Embryonal Carcinoma Stem Cells | 1 | 1998 | 20 | 0.010 |
Why?
|
| Neoplasm Invasiveness | 1 | 2006 | 3618 | 0.010 |
Why?
|
| Bacteria | 1 | 1989 | 2199 | 0.010 |
Why?
|
| Mass Spectrometry | 1 | 2005 | 2192 | 0.010 |
Why?
|
| Bacterial Infections | 1 | 2006 | 1403 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2006 | 3775 | 0.010 |
Why?
|
| Microcirculation | 1 | 2003 | 1278 | 0.010 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2002 | 854 | 0.010 |
Why?
|
| Cytotoxicity Tests, Immunologic | 1 | 1998 | 321 | 0.010 |
Why?
|
| bcl-Associated Death Protein | 1 | 1998 | 102 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 2001 | 1900 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2008 | 5201 | 0.010 |
Why?
|
| Langerhans Cells | 1 | 1998 | 171 | 0.010 |
Why?
|
| Recombinant Proteins | 2 | 1998 | 6538 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2002 | 20509 | 0.010 |
Why?
|
| Chromium | 1 | 1998 | 132 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 18 | 1 | 1998 | 246 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 1998 | 286 | 0.010 |
Why?
|
| Cell Survival | 2 | 1998 | 5797 | 0.010 |
Why?
|
| Embryo, Mammalian | 1 | 2003 | 1674 | 0.010 |
Why?
|
| bcl-2-Associated X Protein | 1 | 1998 | 282 | 0.010 |
Why?
|
| Reactive Oxygen Species | 1 | 2004 | 2138 | 0.010 |
Why?
|
| Cell Aggregation | 1 | 1996 | 239 | 0.010 |
Why?
|
| Cell Adhesion | 1 | 2003 | 3094 | 0.010 |
Why?
|
| bcl-X Protein | 1 | 1998 | 413 | 0.010 |
Why?
|
| Depression | 1 | 2016 | 8044 | 0.010 |
Why?
|
| Gene Expression Regulation | 3 | 1996 | 11903 | 0.010 |
Why?
|
| Nitric Oxide | 1 | 2004 | 2141 | 0.010 |
Why?
|
| Killer Cells, Natural | 1 | 2004 | 2203 | 0.010 |
Why?
|
| Kinetics | 1 | 2002 | 6377 | 0.010 |
Why?
|
| COS Cells | 1 | 1996 | 1129 | 0.010 |
Why?
|
| Conjunctiva | 1 | 1998 | 479 | 0.010 |
Why?
|
| Health Care Surveys | 1 | 2001 | 2435 | 0.010 |
Why?
|
| Collagen | 1 | 2002 | 2636 | 0.010 |
Why?
|
| Quality of Life | 1 | 2016 | 13308 | 0.010 |
Why?
|
| Polymorphism, Genetic | 1 | 2004 | 4291 | 0.010 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2004 | 2895 | 0.010 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 1999 | 1088 | 0.010 |
Why?
|
| Cell Membrane | 1 | 2003 | 3682 | 0.010 |
Why?
|
| Antigen Presentation | 1 | 1998 | 1254 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 1996 | 2753 | 0.010 |
Why?
|
| Proteomics | 1 | 2005 | 3817 | 0.010 |
Why?
|
| Stomach Neoplasms | 1 | 2002 | 1423 | 0.010 |
Why?
|
| Nucleic Acid Hybridization | 2 | 1984 | 1304 | 0.010 |
Why?
|
| Intestinal Mucosa | 1 | 2002 | 3022 | 0.010 |
Why?
|
| Blood Vessels | 1 | 1997 | 1112 | 0.010 |
Why?
|
| Bradykinin | 1 | 1991 | 208 | 0.010 |
Why?
|
| Brain Neoplasms | 1 | 2011 | 8986 | 0.010 |
Why?
|
| Osmolar Concentration | 1 | 1991 | 660 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 1996 | 3602 | 0.010 |
Why?
|
| Bromodeoxyuridine | 1 | 1990 | 311 | 0.010 |
Why?
|
| Antigens, Viral, Tumor | 1 | 1990 | 153 | 0.010 |
Why?
|
| Genes, Regulator | 1 | 1990 | 374 | 0.000 |
Why?
|
| Prostatic Neoplasms | 1 | 1991 | 11345 | 0.000 |
Why?
|
| Capillaries | 1 | 1991 | 744 | 0.000 |
Why?
|
| Attitude of Health Personnel | 1 | 2001 | 3865 | 0.000 |
Why?
|
| Substance-Related Disorders | 1 | 2004 | 4371 | 0.000 |
Why?
|
| Cross-Linking Reagents | 1 | 1990 | 685 | 0.000 |
Why?
|
| Biotechnology | 1 | 1989 | 281 | 0.000 |
Why?
|
| Mice, Inbred Strains | 1 | 1990 | 1763 | 0.000 |
Why?
|
| Clinical Competence | 1 | 2001 | 4783 | 0.000 |
Why?
|
| Peptide Fragments | 1 | 1998 | 5125 | 0.000 |
Why?
|
| Tsetse Flies | 1 | 1984 | 3 | 0.000 |
Why?
|
| Variant Surface Glycoproteins, Trypanosoma | 1 | 1984 | 8 | 0.000 |
Why?
|
| Lung | 1 | 2003 | 9994 | 0.000 |
Why?
|
| Insect Vectors | 1 | 1984 | 134 | 0.000 |
Why?
|
| DNA Restriction Enzymes | 1 | 1982 | 553 | 0.000 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 1985 | 783 | 0.000 |
Why?
|
| Hematopoiesis | 1 | 1990 | 2050 | 0.000 |
Why?
|
| Gene Amplification | 1 | 1984 | 1085 | 0.000 |
Why?
|
| Calcium | 1 | 1991 | 5725 | 0.000 |
Why?
|
| Models, Genetic | 1 | 1984 | 3442 | 0.000 |
Why?
|